ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /
Abstract: SA-PO0430

Remnant Cholesterol Inflammatory Index and C-Reactive Protein-Triglyceride-Glucose Index Surpass CRP in Identifying CKD Severity Among Patients with Cardiovascular-Kidney-Metabolic Syndrome

Session Information

Category: Cardiovascular-Kidney-Metabolic Health

  • 602 Cardiovascular-Kidney-Metabolic Health: Clinical

Authors

  • Chen, Zhicheng, Peking University Health Science Center, Beijing, China
  • Jiang, Shuhan, Peking University Health Science Center, Beijing, China
  • Yu, Ito, Peking University Health Science Center, Beijing, China
  • Bai, Qiong, Peking University Third Hospital, Beijing, China
  • Bao, Wen-Han, Peking University Third Hospital, Beijing, China
  • Zhou, Sijia, Peking University Third Hospital, Beijing, China
  • Wang, Song, Peking University Third Hospital, Beijing, China
  • Tang, Wen, Peking University Third Hospital, Beijing, China
Background

Inflammation and metabolic dysfunction drive cardiorenal damage. Remnant cholesterol inflammatory index (RCII) and CRP-triglyceride glucose index (CTI) are novel inflammatory indicators, but their effectiveness compared with C-reactive protein (CRP) remains undefined. This study aims to compare these indicators for stratifying CKD and CKM syndrome severity.

Methods

Retrospective data of 1644 CKD patients from Peking University Third Hospital (2011–2020) were analyzed. CKD (stage 0–3) and CKM (stage 2–4) risks were stratified. Advanced risk was defined as CKD stage 2–3 and CKM stage 3–4. Multivariate logistic regression, RCS, and ROC analyses were performed. CRP and RCII were log-transformed. Statistics were conducted using SPSS 27 and R 4.5.3.

Results

All indicators showed significant increasing trends across stages (P < 0.001). CRP (log-transformed) was strongly associated with CKM advanced risk (P < 0.001), exhibiting a non-linear relationship with a threshold at 1.47 mg/L. CTI (P < 0.001) and RCII (P < 0.001) also exhibited significant associations with CKM advanced risk. ROC analysis for CKM risk showed AUCs: CRP (0.655) > CTI (0.636) > RCII (0.607). However, CRP (log-transformed) was not significantly associated with CKD risk stratification (P = 0.379). In contrast, RCII (log-transformed) (OR = 1.34, 95% CI: 1.13–1.59, P = 0.001) and CTI (OR = 2.17, 95% CI: 1.28–3.79, P = 0.006) showed a significant linear association with CKD advanced risk.

Conclusion

In the study, CRP excelled in discriminating CKM severity, but it was not independently associated with CKD risk stratification. RCII and CTI could provide superior assessment for CKD risk, serving as robust indicators among patients with CKD and CKM. Further study is needed to evaluate their prognostic utility and explore their associations with various renal etiologies.

Funding

  • Clinical Revenue Support